Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Prime Minister Narendra Modi attended an event marking the 100th robotic-assisted surgical system installation at U. N. Mehta Institute of Cardiology, Ahmedabad.
Ties up with Denmark’s Vestfrost Solutions, to cater to the unique needs of the Indian market
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Subscribe To Our Newsletter & Stay Updated
